Search research articles
Contact Us
Filters
Showing results (301-310 of 319) with videos related to
Page
of 32
Sort By:
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
BMC Medicine
|
January 14, 2022
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection
Feargal J Ryan, Christopher M Hope, Makutiro G Masavuli, et al.
Annals of the Rheumatic Diseases
|
October 13, 2017
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative
Jasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Jason Grebely, Olav Dalgard, Brian Conway, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 319) with videos related to
Sort By:
Page
of 32
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
BMC Medicine
|
January 14, 2022
Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection
Feargal J Ryan, Christopher M Hope, Makutiro G Masavuli, et al.
Annals of the Rheumatic Diseases
|
October 13, 2017
Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative
Jasmin B Kuemmerle-Deschner, Sandra Hansmann, Nico M Wulffraat, et al.
The International Journal on Drug Policy
|
November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy
Jason Grebely, Brian Conway, Evan B Cunningham, et al.
The International Journal on Drug Policy
|
October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study
Evan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet. Gastroenterology & Hepatology
|
January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
Jason Grebely, Olav Dalgard, Brian Conway, et al.
Journal of Hepatology
|
June 14, 2019
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M Borgia, Janet Dearden, Eric M Yoshida, et al.
Page
of 32